01.30.25 -- How Does A Successful Client-CDMO Partnership Meet Challenges?

A CDMO’s manufacturing science and technology (MSAT) plays a critical role in optimizing a biomanufacturing process to meet the needs of the modern healthcare landscape.

As pharma companies aim to overcome development obstacles, it is important to incorporate GMP expertise alongside novel technologies that can enhance the properties of APIs and dosage forms.

Extracellular vesicles hold immense potential for treating diseases, owing to their natural biocompatibility and ability to carry a diverse arsenal of therapeutic molecules.

It is important to consider several factors in the overall development approach during the early phases in order to de-risk the late-phase development of your biologic drug product.

Realize the importance of alternative approaches to viral vector production and the benefits of intensified adherent cell culture for improving efficiency, reducing costs, and accelerating development.

Understanding the Fc region of your antibody is crucial for assessing the impact on immunology, safety, and efficacy. Explore how to determine the most efficient way to test functionality.

Review advice to pharma companies on three key areas of auto-injector device development: patient-centered design, container and device considerations, and manufacturing partner selection.